Surging demand for weight loss and diabetes medications is creating a potential 'bubble effect' within the pharmaceutical sector, according to a new report. This concentration of revenue streams raises concerns about the underlying health of the broader industry.
GLP-1s Drive Pharma R&D Returns
- Pharmaceutical Research & Development (R&D) returns for the top 20 global pharma companies have improved for the third consecutive year, reaching 7%.* This growth is attributed almost entirely to a small group of high-forecast assets, notably the glucagon-like peptide receptor agonists (GLP-1s).
Obesity Treatments Overtake Oncology
Deloitte's report highlights a significant shift in the industry's pipeline value:
- For the first time in 16 years, obesity treatments have surpassed oncology as the largest contributor to late-stage pipeline value.
Concentration Risks Identified
Industry experts warn that this heavy reliance on specific therapeutic areas increases corporate vulnerability to targeted shocks.
- Market Concentration: Drugs targeting obesity and diabetes are estimated to account for 38% of all projected commercial inflows from the 2025 late-stage pipeline.
- Bubble Warning: Hanno Ronte, a Life Sciences and Healthcare Partner at Deloitte, stated, "It is a bubble, because so much is concentrated."
- Underlying Weakness: The report suggests that excluding GLP-1/GIP assets reveals a weaker underlying environment for the rest of the industry. If these assets are removed from the analysis, the industry's rate of return drops to 2.9%, down from 3.8% in 2024.
